| Dr Jemilat Olapeju Badamas, MD | |
|
1221 Mercantile Ln, Largo, MD 20774-5374 | |
| (301) 618-5500 | |
| Not Available |
| Full Name | Dr Jemilat Olapeju Badamas |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 15 Years |
| Location | 1221 Mercantile Ln, Largo, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427292093 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | XXXXXXXXX (Maryland) | Secondary |
| 207RG0100X | Internal Medicine - Gastroenterology | D0075154 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
News Archive
Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.
HHS announced Tuesday that it "has begun accepting applications for the early retiree reinsurance program created by the new health law. The law sets aside $5 billion that businesses, unions and state and local governments can use to cover the healthcare costs of their retirees — and their spouses and dependents — who are older than 55 but don't yet qualify for Medicare." Some are worried that money for that program won't last through 2014, when other parts of the law take effect.
A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer's and gout.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.
HHS announced Tuesday that it "has begun accepting applications for the early retiree reinsurance program created by the new health law. The law sets aside $5 billion that businesses, unions and state and local governments can use to cover the healthcare costs of their retirees — and their spouses and dependents — who are older than 55 but don't yet qualify for Medicare." Some are worried that money for that program won't last through 2014, when other parts of the law take effect.
A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer's and gout.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1578638425 PECOS PAC ID: 3779495858 Enrollment ID: O20040805001280 |
News Archive
Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.
HHS announced Tuesday that it "has begun accepting applications for the early retiree reinsurance program created by the new health law. The law sets aside $5 billion that businesses, unions and state and local governments can use to cover the healthcare costs of their retirees — and their spouses and dependents — who are older than 55 but don't yet qualify for Medicare." Some are worried that money for that program won't last through 2014, when other parts of the law take effect.
A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer's and gout.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1073678637 PECOS PAC ID: 3779495858 Enrollment ID: O20100729000796 |
News Archive
Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.
HHS announced Tuesday that it "has begun accepting applications for the early retiree reinsurance program created by the new health law. The law sets aside $5 billion that businesses, unions and state and local governments can use to cover the healthcare costs of their retirees — and their spouses and dependents — who are older than 55 but don't yet qualify for Medicare." Some are worried that money for that program won't last through 2014, when other parts of the law take effect.
A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer's and gout.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1366781700 PECOS PAC ID: 3779495858 Enrollment ID: O20130507000207 |
News Archive
Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.
HHS announced Tuesday that it "has begun accepting applications for the early retiree reinsurance program created by the new health law. The law sets aside $5 billion that businesses, unions and state and local governments can use to cover the healthcare costs of their retirees — and their spouses and dependents — who are older than 55 but don't yet qualify for Medicare." Some are worried that money for that program won't last through 2014, when other parts of the law take effect.
A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer's and gout.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 8 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1497023188 PECOS PAC ID: 3779495858 Enrollment ID: O20131029000108 |
News Archive
Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.
HHS announced Tuesday that it "has begun accepting applications for the early retiree reinsurance program created by the new health law. The law sets aside $5 billion that businesses, unions and state and local governments can use to cover the healthcare costs of their retirees — and their spouses and dependents — who are older than 55 but don't yet qualify for Medicare." Some are worried that money for that program won't last through 2014, when other parts of the law take effect.
A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer's and gout.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jemilat Olapeju Badamas, MD 1221 Mercantile Ln, Largo, MD 20774-5374 Ph: (301) 618-5500 | Dr Jemilat Olapeju Badamas, MD 1221 Mercantile Ln, Largo, MD 20774-5374 Ph: (301) 618-5500 |
News Archive
Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.
HHS announced Tuesday that it "has begun accepting applications for the early retiree reinsurance program created by the new health law. The law sets aside $5 billion that businesses, unions and state and local governments can use to cover the healthcare costs of their retirees — and their spouses and dependents — who are older than 55 but don't yet qualify for Medicare." Some are worried that money for that program won't last through 2014, when other parts of the law take effect.
A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer's and gout.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 8 days ago
Dr. Lynn Anetta Thomas, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1221 Mercantile Ln, Kaiser Permanente Largo Medical Center, Largo, MD 20774 Phone: 301-618-5500 | |
Dr. Rupa Allam Varma, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1221 Mercantile Avenue, Largo, MD 20774 Phone: 301-618-5500 Fax: 301-618-5673 | |
Dr. Doreen Blake, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1450 Mercantile Ln, Suite 111, Largo, MD 20774 Phone: 301-925-7610 | |
Dr. Nancy Fleurancois, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1221 Mercantile Ln Ste 102, Largo, MD 20774 Phone: 301-368-1500 | |
Dr. Cielito M Aguinaldo, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1221 Mercantile Ln, Kaiser Permanente Largo Medical Center, Largo, MD 20774 Phone: 301-618-5500 | |
Dr. Surendra M Kumar, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1100 Mercantile Ln, Ste 135, Largo, MD 20774 Phone: 301-773-9700 | |
Dr. Jerry Wendell Mcconnell, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1221 Mercantile Lane, Largo, MD 20774 Phone: 301-618-5578 Fax: 301-618-5673 |